Beyond vision: The overlooked burden of depression in glaucoma patients

Table 1 Evidence linking glaucoma and depression with clinical implications

Domain	Key finding (as reported)	Clinical implication	Ref.
Prevalence	Depression ≈ 19% and anxiety ≈ 25% among glaucoma patients; higher than in controls	Mental-health burden is substantial; routine screening is warranted	[16]
Population-based variance	In the Gutenberg Health Study, depression prevalence was similar in self-reported mild glaucoma (about 6.6%) vs non-glaucoma (about 7.7%); no significant adjusted association	Community cases (often earlier/treated) may show lower psychiatric burden than hospital cohorts	[5]
Multicenter (Brazil)	Depression 26.9% (vs about 5.8% national baseline) and anxiety 25.7%; depression was more frequent in severe glaucoma	Screen across stages, with extra attention in severe disease	[22]
Glaucoma → depression	Having glaucoma increased subsequent depression risk (adjusted HR ≈ 1.71)	Monitor mood longitudinally after glaucoma diagnosis	[10,23]
Depression → glaucoma	Depression is associated with a higher incidence of glaucoma (HR ≈ 1.12), rising to ≈ 1.36 with both disorder and symptoms; a stepwise pattern	Depressed patients merit closer ophthalmic surveillance	[11]
Bidirectional/biobank	United Kingdom Biobank: Depression linked to incident glaucoma (HR ≈ 1.35); bidirectional association (odds ≈ 1.6 in both directions); proteomics suggests lipid-related pathways	Supports integrated eye-mental-health models; points to biological links	[12]
Glaucoma → hospitalized MH events	Increased risks among glaucoma patients: Hospitalized depression (HR = 1.54) and anxiety (HR = 2.61); polygenic overlap; limited MR support for causality	Elevated psychiatric risk even without clear genetic causality; clinical vigilance needed	[14,16]
Antidepressants and risk	Prolonged/high-dose SSRI exposure was associated with higher glaucoma incidence during follow-up (adjusted OR = 1.36 for > 365 days/cumulative dose)	Weigh risks in predisposed patients; coordinate with psychiatry/PCP	[13]
Adherence → outcomes	Poorer adherence was associated with faster visual-field loss (CIGTS)	Address mood/anxiety to protect adherence and visual outcomes	[17]
Distress and adherence	Higher glaucoma-related distress forecast worse adherence; coaching factors identified	Incorporate coaching/psychoeducation into care pathways	[19]
OSD + anxiety → compliance	In veterans, ocular surface discomfort with anxiety symptoms linked to lower medication compliance	Treat ocular surface disease and anxiety to improve adherence	[28]
Mood and progression	Higher anxiety correlated with faster RNFL thinning and more disc hemorrhages; higher depression associated with worse baseline fields and altered HRV	Positive screens may flag patients at risk for faster progression	[7]
Screening tools (feasibility)	Brief tools (PHQ-9, GAD-7; HADS; BDI-II) are feasible in ophthalmic care; telephone administration is possible; multicenter implementation supports referral decisions	Embed PHQ-9/GAD-7 at diagnosis and key milestones; create clear referral pathways	[33-37]
Medication caveats	Topical β-blockers may precipitate depressive symptoms in susceptible individuals (conflicting data exist). Rare angle-closure with SSRIs/SNRIs in predisposed patients; case report of duloxetine. Reviews summarize IOP/angle interactions	Review systemic/ocular meds jointly; educate narrow-angle patients on warning signs	[38-40,75,76,82]
Psychological stress and IOP	Acute emotional stress can trigger IOP spikes; experimental/clinical data link stress to IOP changes; RCT explored stress and IOP dynamics	Offer stress-management strategies alongside IOP control	[68,83,92]
Interventions	CBT improved QoL in glaucoma/cataract patients with mild-moderate depression; low-vision rehabilitation was effective; coaching improved adherence; digital adherence monitoring and tele-ophthalmology were useful	Combine psychotherapy, rehab, coaching, and digital tools to support engagement	[43-48,94]
Global burden	Projected 111 million people with glaucoma by 2040; substantial global blindness/VI burden	Scaling integrated eye-mental-health care is a public-health priority	[20,97]

HR: Hazard ratio; MH: Mental health; MR: Magnetic resonance; SSRI: Selective serotonin reuptake inhibitor; OR: Odds ratio; PCP: Primary care physician; CIGTS: Collaborative Initial Glaucoma Treatment Study; OSD: Ocular surface disease; RNFL: Retinal nerve fiber layer; PHQ-9: Patient Health Questionnaire-9; GAD-7: Generalized Anxiety Disorder-7; HADS: Hospital Anxiety and Depression Scale; BDI-II: Beck Depression Inventory-II; SSRIs: Selective serotonin reuptake inhibitors; SNRIs: Serotonin-norepinephrine reuptake inhibitors; IOP: Intraocular pressure; RCT: Randomized controlled trial; CBT: Cognitive behavioral therapy; QoL: Quality of life; VI: Visual impairment; HRV: Heart rate variability.